AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10696837 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton-pump inhibitor therapy
Number of subjects: 0
Study 10696837 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopy
Number of subjects: 0
Study 10696837 — intervention group
Group type: EXPERIMENTAL
Intervention: Ablation techniques
Number of subjects: 0
Study 10696837 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic follow-up
Number of subjects: 0
Study 9125824 — intervention group
Group type: EXPERIMENTAL
Intervention: Wavelet and wavelet packet compression (8:1 compression)
Number of subjects: 0
Study 9125824 — intervention group
Group type: EXPERIMENTAL
Intervention: Wavelet and wavelet packet compression (16:1 compression)
Number of subjects: 0
Study 8252157 — intervention group
Group type: COMPARATOR
Intervention: Ceftazidime alone 3 g/day (Group C)
Number of subjects: 102
Study 8252157 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftazidime 3 g/day plus amikacin 15 mg/kg/day (Group CA)
Number of subjects: 102
Study 8252157 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftazidime 3 g/day plus vancomycin 1.5 g/day (Group CV)
Number of subjects: 102
Study 3896716 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenytoin
Number of subjects: 151
Study 3896716 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 151
Study 29741974 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumoperitoneum pressure of 8 mm Hg (n=18)
Number of subjects: 36
Study 29741974 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumoperitoneum pressure of 12 mm Hg (n=18)
Number of subjects: 36
Study 27288307 — intervention group
Group type: EXPERIMENTAL
Intervention: Tβ4-pre-treated EPC transplantation (experimental group)
Number of subjects: 10
Study 27288307 — intervention group
Group type: COMPARATOR
Intervention: EPC transplantation (control group)
Number of subjects: 10
Study 25491069 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepped psychosocial care (screening for distress, doctor consultation, transferal to consultation liaison service)
Number of subjects: 1000
Study 25491069 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (control group)
Number of subjects: 1000
Study 22781566 — intervention group
Group type: EXPERIMENTAL
Intervention: Shadow boxing exercise for 3 months
Number of subjects: 70
Study 22781566 — intervention group
Group type: COMPARATOR
Intervention: Conventional out‐hospital management
Number of subjects: 70
Study 20424219 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide
Number of subjects: 69
Study 20424219 — intervention group
Group type: COMPARATOR
Intervention: Insulin glargine
Number of subjects: 69
Study 18695132 — intervention group
Group type: EXPERIMENTAL
Intervention: Radical prostatectomy
Number of subjects: 695
Study 18695132 — intervention group
Group type: COMPARATOR
Intervention: Watchful waiting
Number of subjects: 695
Study 18695132 — intervention group
Group type: EXPERIMENTAL
Intervention: Radical prostatectomy with extracapsular tumor growth
Number of subjects: 695
Study 15939243 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids (ICS) therapy for 2 months
Number of subjects: 47
Study 15939243 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids (ICS) therapy
Number of subjects: 47
Study 12818902 — intervention group
Group type: EXPERIMENTAL
Intervention: Long chain polyunsaturated fatty acids (LCPUFA), including docosahexaenoic acid (DHA)
Number of subjects: 20
Study 12818902 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 10365035 — intervention group
Group type: EXPERIMENTAL
Intervention: Heidelberg retina tomograph (HRT) analysis in converters
Number of subjects: 26
Study 10365035 — intervention group
Group type: COMPARATOR
Intervention: Normal control subjects
Number of subjects: 26
Study 8916749 — intervention group
Group type: EXPERIMENTAL
Intervention: Xylitol chewing gum (8.4 g a day)
Number of subjects: 306
Study 8916749 — intervention group
Group type: COMPARATOR
Intervention: Sucrose chewing gum (control)
Number of subjects: 306
Study 1927519 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) dose regimen of 15 IU/m2/week as daily s.c. injections
Number of subjects: 32
Study 1927519 — intervention group
Group type: COMPARATOR
Intervention: Growth hormone (GH) dose regimen of 30 IU/m2/week
Number of subjects: 32
Study 6350994 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous guanethidine block
Number of subjects: 19
Study 6350994 — intervention group
Group type: COMPARATOR
Intervention: Stellate ganglion block
Number of subjects: 19
Study 30732624 — intervention group
Group type: EXPERIMENTAL
Intervention: Carer-administration of as-needed subcutaneous medication for breakthrough symptoms (pain, nausea, restlessness, noisy breathing) with manualised training package delivered by local nursing team.
Number of subjects: 0
Study 30732624 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control arm).
Number of subjects: 0
Study 29742243 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline (25 mg/day)
Number of subjects: 97
Study 29742243 — intervention group
Group type: EXPERIMENTAL
Intervention: NTI‐tss
Number of subjects: 97
Study 29742243 — intervention group
Group type: EXPERIMENTAL
Intervention: Non‐occlusal splint
Number of subjects: 97
Study 27346173 — intervention group
Group type: EXPERIMENTAL
Intervention: Lottery-based commitment device
Number of subjects: 163
Study 27346173 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 163
Study 24650849 — intervention group
Group type: EXPERIMENTAL
Intervention: Low radiation CTLS with 150 mAs tube current and 120 kVp tube voltage (Group A)
Number of subjects: 0
Study 24650849 — intervention group
Group type: EXPERIMENTAL
Intervention: Low radiation CTLS with 230 mAs tube current and 100 kVp tube voltage (Group B)
Number of subjects: 0
Study 24650849 — intervention group
Group type: COMPARATOR
Intervention: Control group (filtered back-projection)
Number of subjects: 0
Study 22962971 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief dynamic psychotherapy (12 weeks)
Number of subjects: 40
Study 22962971 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU)
Number of subjects: 40
Study 22962971 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief dynamic psychotherapy
Number of subjects: 40
Study 20884622 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous tumor lysate- and KLH-pulsed DC vaccine
Number of subjects: 26
Study 20884622 — intervention group
Group type: EXPERIMENTAL
Intervention: DCs activated with CD40L
Number of subjects: 26
Study 20884622 — intervention group
Group type: COMPARATOR
Intervention: KLH-specific immune responses
Number of subjects: 26
Study 18629727 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine patch
Number of subjects: 128
Study 18629727 — intervention group
Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 128
Study 15982130 — intervention group
Group type: EXPERIMENTAL
Intervention: Feature search task with preknowledge of target dimension
Number of subjects: 0
Study 15982130 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonsearch task with preknowledge of target dimension
Number of subjects: 0
Study 15982130 — intervention group
Group type: EXPERIMENTAL
Intervention: Trial-by-trial cueing with preknowledge of target dimension
Number of subjects: 0
Study 12373264 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive social worker-based education program and environmental control
Number of subjects: 1033
Study 12373264 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1033
Study 10648338 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol/sufentanil anesthesia (0.01 microg. kg(‐1). min(‐1))
Number of subjects: 20
Study 10648338 — intervention group
Group type: COMPARATOR
Intervention: Enflurane anesthesia
Number of subjects: 20
Study 10648338 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol/sufentanil anesthesia
Number of subjects: 20
Study 8710194 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium-latency responses (MLR)
Number of subjects: 0
Study 8710194 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-latency responses (SLR)
Number of subjects: 0
Study 8710194 — intervention group
Group type: EXPERIMENTAL
Intervention: Conduction velocity of afferent fibres mediating FDB MLR
Number of subjects: 0
Study 1506154 — intervention group
Group type: EXPERIMENTAL
Intervention: Gadoteridol
Number of subjects: 122
Study 6522737 — intervention group
Group type: EXPERIMENTAL
Intervention: Counseling sessions (6 sessions over 6 months)
Number of subjects: 163
Study 6522737 — intervention group
Group type: COMPARATOR
Intervention: No counseling (Control group)
Number of subjects: 163
Study 31016897 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal intervention (individualized resistance exercise for 16 weeks, structured diabetes and nutritional education over seven sessions, investigator-linked training)
Number of subjects: 964
Study 31016897 — intervention group
Group type: COMPARATOR
Intervention: Usual care group (UCG)
Number of subjects: 964
Study 31016897 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost-effectiveness of the intervention
Number of subjects: 964
Study 31016897 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary outcomes (mortality, hospitalization, institutionalization, quality of life, burden on caregivers, frequency and severity of hypoglycaemia episodes)
Number of subjects: 964
Study 29289798 — intervention group
Group type: EXPERIMENTAL
Intervention: Moral stories emphasizing actors' negative emotions toward their nonhelping behavior
Number of subjects: 322
Study 29289798 — intervention group
Group type: EXPERIMENTAL
Intervention: Other moral stories with a helping theme
Number of subjects: 322
Study 29289798 — intervention group
Group type: COMPARATOR
Intervention: Nonmoral story (control group)
Number of subjects: 322
Study 26510632 — intervention group
Group type: EXPERIMENTAL
Intervention: Dog visits
Number of subjects: 100
Study 26510632 — intervention group
Group type: COMPARATOR
Intervention: Robot seal visits
Number of subjects: 100
Study 26510632 — intervention group
Group type: COMPARATOR
Intervention: Soft toy cat visits
Number of subjects: 100
Study 26510632 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental period (all visit types)
Number of subjects: 100
Study 25098116 — intervention group
Group type: EXPERIMENTAL
Intervention: Metipred and cyclosporine
Number of subjects: 27
Study 25098116 — intervention group
Group type: COMPARATOR
Intervention: Conventional prevention (topical corticosteroids)
Number of subjects: 27
Study 22989898 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive SBP reduction (to <=140mmHg) using intravenous nicardipine infusion for 24 hours post-randomization
Number of subjects: 1280
Study 22989898 — intervention group
Group type: COMPARATOR
Intervention: Standard SBP reduction (to 140-180mmHg)
Number of subjects: 1280
Study 20171656 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil
Number of subjects: 28
Study 20171656 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 18021872 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone 30 mg daily for 4 weeks, followed by 45 mg daily for 12 weeks
Number of subjects: 26
Study 18021872 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 16040446 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose xylitol (HX; 6.0 g xylitol)
Number of subjects: 11
Study 16040446 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose xylitol (LX; 2.0 g xylitol)
Number of subjects: 11
Study 16040446 — intervention group
Group type: COMPARATOR
Intervention: Control (CTR; no xylitol)
Number of subjects: 11
Study 11846205 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioactive glass (BG)
Number of subjects: 30
Study 11846205 — intervention group
Group type: EXPERIMENTAL
Intervention: Demineralized freeze-dried bone allograft (DFDBA)
Number of subjects: 30
Study 11846205 — intervention group
Group type: COMPARATOR
Intervention: Unfilled control (C)
Number of subjects: 30
Study 12296423 — intervention group
Group type: EXPERIMENTAL
Intervention: Trained hypokinetic subjects (THKS)
Number of subjects: 40
Study 12296423 — intervention group
Group type: EXPERIMENTAL
Intervention: Untrained hypokinetic subjects (UHKS)
Number of subjects: 40
Study 12296423 — intervention group
Group type: COMPARATOR
Intervention: Trained ambulatory control subjects (TACS)
Number of subjects: 40
Study 12296423 — intervention group
Group type: COMPARATOR
Intervention: Untrained ambulatory control subjects (UACS)
Number of subjects: 40
Study 12296423 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison between THKS and UHKS
Number of subjects: 40
Study 9839589 — intervention group
Group type: EXPERIMENTAL
Intervention: p53 autoantibodies positive patients (13 patients with cancer)
Number of subjects: 198
Study 9839589 — intervention group
Group type: COMPARATOR
Intervention: Control group (1 patient with benign disease)
Number of subjects: 198
Study 8009976 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-beta (2 x 10(6) I.U. daily) for ten days
Number of subjects: 37
Study 8009976 — intervention group
Group type: COMPARATOR
Intervention: Placebo (2 ml of saline solution daily) for ten days
Number of subjects: 37
Study 2782336 — intervention group
Group type: EXPERIMENTAL
Intervention: Group I: Clindamycin and tobramycin for >= 24 hours
Number of subjects: 109
Study 2782336 — intervention group
Group type: EXPERIMENTAL
Intervention: Group II: Clindamycin and tobramycin for >= 48 hours
Number of subjects: 109
Study 2782336 — intervention group
Group type: EXPERIMENTAL
Intervention: Group III: Clindamycin and tobramycin for >= 48 hours followed by 7-day course of oral Augmentin
Number of subjects: 109
Study 991009 — intervention group
Group type: EXPERIMENTAL
Intervention: Home care after surgery
Number of subjects: 0
Study 991009 — intervention group
Group type: COMPARATOR
Intervention: Hospital care after surgery
Number of subjects: 0
Study 7031859 — intervention group
Group type: EXPERIMENTAL
Intervention: 40% idoxuridine (IDU) dissolved in dimethyl sulphoxide (DMSO)
Number of subjects: 122
Study 7031859 — intervention group
Group type: COMPARATOR
Intervention: DMSO and saline flavoured with garlic (Control)
Number of subjects: 122
Study 31350526 — intervention group
Group type: EXPERIMENTAL
Intervention: Veliparib plus FOLFIRI±bevacizumab
Number of subjects: 0
Study 31350526 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus FOLFIRI±bevacizumab
Number of subjects: 0
Study 29300197 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucrose solution (25%; 0.5 mL/kg) administered 2 minutes before procedures
Number of subjects: 104
Study 29300197 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 104
Study 27611054 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine infusion
Number of subjects: 75
Study 27611054 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 75
Study 25357253 — intervention group
Group type: EXPERIMENTAL
Intervention: Proxy high-EE speech sample
Number of subjects: 38
Study 25357253 — intervention group
Group type: COMPARATOR
Intervention: Neutral speech samples
Number of subjects: 38
Study 22622278 — intervention group
Group type: EXPERIMENTAL
Intervention: EMDR treatment with one-week sessions
Number of subjects: 0
Study 22622278 — intervention group
Group type: COMPARATOR
Intervention: Sertraline (SSRI) treatment
Number of subjects: 0
Study 20195553 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-controlled oral analgesia (PCOA)
Number of subjects: 88
Study 20195553 — intervention group
Group type: COMPARATOR
Intervention: RN-administered short-acting oral opioids
Number of subjects: 88
Study 20195553 — intervention group
Group type: EXPERIMENTAL
Intervention: PCOA
Number of subjects: 88
Study 20195553 — intervention group
Group type: COMPARATOR
Intervention: RN administration
Number of subjects: 88
Study 18805154 — intervention group
Group type: EXPERIMENTAL
Intervention: Processed shed blood (treated)
Number of subjects: 266
Study 18805154 — intervention group
Group type: COMPARATOR
Intervention: Unprocessed shed blood (control)
Number of subjects: 266
Study 15956047 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron medicine (ferrous gluconate at 3 mg/kg of elemental iron once daily)
Number of subjects: 234
Study 15956047 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron fortified follow-on milk (12 mg/l ferrous iron)
Number of subjects: 234
Study 15956047 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron fortified partially modified cows' milk (12.9 mg/l ferrous iron)
Number of subjects: 234
Study 12095498 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg of clomiphene citrate (CC) on days 1-5
Number of subjects: 33
Study 12095498 — intervention group
Group type: COMPARATOR
Intervention: Placebo on days 1-5
Number of subjects: 33
Study 11503828 — intervention group
Group type: EXPERIMENTAL
Intervention: Etidronic acid (disodium etidronate)
Number of subjects: 3
Study 11503828 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3
Study 8707127 — intervention group
Group type: EXPERIMENTAL
Intervention: Sclerotherapy plus propranolol
Number of subjects: 200
Study 8707127 — intervention group
Group type: COMPARATOR
Intervention: Sclerotherapy alone
Number of subjects: 200
Study 1922235 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefixime 400 mg (oral)
Number of subjects: 333
Study 1922235 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefixime 800 mg (oral)
Number of subjects: 333
Study 1922235 — intervention group
Group type: COMPARATOR
Intervention: Ceftriaxone 250 mg (intramuscular)
Number of subjects: 333
Study 6981167 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole (TMP-SMZ) - 160 mg of TMP plus 800 mg of SMZ, two double-strength tablets twice daily for two days
Number of subjects: 69
Study 6981167 — intervention group
Group type: COMPARATOR
Intervention: Ampicillin plus probenecid - 3.5 g of ampicillin plus 1 g of probenecid, single dose
Number of subjects: 69
Study 6981167 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole (TMP-SMZ)
Number of subjects: 69
Study 6981167 — intervention group
Group type: COMPARATOR
Intervention: Ampicillin plus probenecid
Number of subjects: 69
Study 30819688 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab (BVB) 1.25 mg
Number of subjects: 58
Study 30819688 — intervention group
Group type: COMPARATOR
Intervention: Triamcinolone acetonide (TA) 4 mg
Number of subjects: 58
Study 29402270 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin treatment group
Number of subjects: 274
Study 29402270 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment group
Number of subjects: 274
Study 27621258 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-help cognitive behaviour therapy (CBT) intervention lasting 4 weeks
Number of subjects: 100
Study 27621258 — intervention group
Group type: COMPARATOR
Intervention: No treatment-wait control condition (NTWC)
Number of subjects: 100
Study 24899268 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB)
Number of subjects: 69
Study 24899268 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic adjustable gastric banding (LAGB)
Number of subjects: 69
Study 24899268 — intervention group
Group type: COMPARATOR
Intervention: Intensive lifestyle weight loss intervention (LWLI)
Number of subjects: 69
Study 22105940 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual axis rotational coronary angiography (DARA)
Number of subjects: 463
Study 22105940 — intervention group
Group type: COMPARATOR
Intervention: Conventional single and biplane coronary imaging
Number of subjects: 463
Study 20197013 — intervention group
Group type: EXPERIMENTAL
Intervention: Saquinavir/ritonavir 1,000/100 mg twice daily for 2 weeks
Number of subjects: 17
Study 20197013 — intervention group
Group type: COMPARATOR
Intervention: Control (baseline digoxin dose of 0.5 mg)
Number of subjects: 17
Study 17437688 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective serotonin reuptake inhibitors (SSRIs); specific dosage and duration not available
Number of subjects: 0
Study 15560958 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg/day clozapine
Number of subjects: 47
Study 15560958 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg/day clozapine
Number of subjects: 47
Study 15560958 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg/day clozapine
Number of subjects: 47
Study 15560958 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg/day clozapine (heavy smokers)
Number of subjects: 47
Study 12930926 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factor (G-CSF) given concurrently with chemotherapy
Number of subjects: 640
Study 12930926 — intervention group
Group type: COMPARATOR
Intervention: No G-CSF
Number of subjects: 640
Study 12930926 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factor (G-CSF) in standard-risk AML
Number of subjects: 640
Study 12930926 — intervention group
Group type: COMPARATOR
Intervention: No G-CSF in standard-risk AML
Number of subjects: 640
Study 12930926 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factor (G-CSF) in unfavorable prognosis subgroup
Number of subjects: 640
Study 10519559 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexion‐distraction technique (active treatment)
Number of subjects: 18
Study 10519559 — intervention group
Group type: COMPARATOR
Intervention: Sham adjustments (placebo treatment)
Number of subjects: 18
Study 7856781 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity interventions integrated into routine prenatal care
Number of subjects: 0
Study 7856781 — intervention group
Group type: COMPARATOR
Intervention: Control clinics
Number of subjects: 0
Study 2391397 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen sustained release (SR) high dose (2000 mg)
Number of subjects: 200
Study 2391397 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen immediate plus sustained release (IR + SR) high dose (500 + 1500 mg)
Number of subjects: 200
Study 2391397 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen standard tablet high dose (1000 mg)
Number of subjects: 200
Study 2391397 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen standard tablet low dose (500 mg)
Number of subjects: 200
Study 2391397 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen sustained release (SR) low dose (1000 mg)
Number of subjects: 200
Study 2391397 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen immediate plus sustained release (IR + SR) low dose (250 + 750 mg)
Number of subjects: 200